Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
IPO Year: n/a
Exchange: NASDAQ
Website: sinovacbio.com
SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)
SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)
SC 13G/A - SINOVAC BIOTECH LTD (0001084201) (Subject)
SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)
SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)
SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)
SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)
SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London, England, has ruled that the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was the rightfully elected Board of SINOVAC. The Privy Council also ruled that the Company's Rights Agreement is invalid. The ruling will take effect after entry of a court order expected within a week. SINOVAC's outgoing Board members are committed to ensuring a smooth transition with the new Board members and to preserving SINOVAC's significant value for the benefit of all sha
The first phase III clinical trial on a multivalent HFMD vaccine in the world Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phase III clinical trial on a vaccine candidate to prevent HFMD caused by both Enterovirus 71 (EV71) and Coxsackievirus 16 (CA16). Notably, no multivalent vaccines against HFMD have yet been approved for marketing worldwide. The Phase III clinical trial is designed to be a multicenter, randomized, double-blind, controlled trial to evaluate the efficacy, safety and immunogenicity of this vaccine candidate in infants and young children aged 6 to 71 month
Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2024 to February 22, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, pol
Board of Directors Unanimously Recommends Sinovac Shareholders NOT Tender Shares for purchase pursuant to the Offer to Purchase Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the "Board of Directors") unanimously determined that the partial tender offer (the "Tender Offer") by Alternative Liquidity Index LP ("Alternative Liquidity") to acquire up to 10,000,000 common shares of Sinovac (the "Shares") for $0.03 per share in cash (the "Offer Price") is NOT advisable and is NOT in the best interests of the Company or its shareholders ("Shareholders"). Accordingly, the Board
Clinical trials will advance treatment of COVID-19 infection. Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection ("SA55 Injection") in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently. SINOVAC's SA55 Injection, which is intended for the treatment of COVID-19 infections, was approved for clinical trial in China on May 24, 2023. The phase I clinical trial has confirmed its preliminar
Board of Directors Unanimously Recommends Sinovac Shareholders NOT Tender Shares for purchase pursuant to the Offer to Purchase Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the "Board of Directors") unanimously determined that the partial tender offer (the "Tender Offer") by Alternative Liquidity Index LP ("Alternative Liquidity") to acquire up to 10,000,000 common shares of Sinovac (the "Shares") for $0.03 per share in cash (the "Offer Price") is NOT advisable and is NOT in the best interests of the Company or its shareholders ("Shareholders"). Accordingly, the Board
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, confirmed today that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company's outstanding shares, for $0.03 per share in cash. Sinovac's Board of Directors intends to evaluate the terms of the tender offer to determine the course of action that it believes is in the best interest of the Company and its shareholders. The Board also intends to advise shareholders of the Board's position regarding the tender offer within ten bu
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that the Company's subsidiary, Sinovac Biotech Co., Ltd. ("Sinovac Beijing"), has changed its legal representative to Mr. Weidong Yin, the Company's Chairman, President and Chief Executive Officer. The Administration for Market Regulation Bureau of Beijing Haidian District notified Sinovac Beijing that the minority shareholder and the legal representative of Sinovac Beijing have been changed in accordance with the Notice of Assistance of Court Verdict Execution, the Verdict Execution Order and the Consent Judgement on the Civil Mediation Agreement by S
Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2023 to February 22, 2024. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pn
Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health Organization (WHO) for its live attenuated varicella vaccine on November 3, 2022. This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval. The varicella vaccine is derived from the Oka strain and propagated in SINOVAC's proprietary Human Diploid Cell (SV-1 strain), which is made by culturing and harvesting the virus, adding stabilizers and freeze-drying. According to a phase III efficacy study, the seroconversion rate of the vaccinated
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021. The Company also reported its unaudited financial for the second half and full year ended December 31, 2021. Second Half and Full Year 2021 Financial Summary Sales for the six months ended December 31, 2021 were $8.4 billion, compared to $442.9 million in the prior year period. Sales in 2021 were $19.4 billion, compared to $510.6 million in the prior year. The Company posted $3.4 billion of net income attributable to common sharehol
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2021. First Half of 2021 Financial Summary Sales for the six months ended June 30, 2021 were $11.0 billion, compared to $67.7 million in the prior year period. The Company posted $5.1 billion of net income attributable to common shareholders, or $51.42 per basic and $44.80 per diluted share, in the six months ended June 30, 2021, compared to net loss attributable to common shareholders of $12.6 million, or $0.13 loss per basic and diluted share, in the prior year period. Mr. Weidon
Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2020. The Company also reported its unaudited financial results for the fourth quarter ended December 31, 2020. Fourth Quarter and Full Year 2020 Financial Summary Sales for the fourth quarter of 2020 were $327.5 million, an increase from $81.1 million in the prior year period. Sales in 2020 were $510.6 million, an increase from $246.1 million in the prior year. Operating income for the fourth quarter increased by 583.7% from the prior
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the third quarter ended September 30, 2020. Third Quarter and Nine Months Ended 2020 Financial Summary Sales for the third quarter of 2020 were $115.5 million, an increase of 79.4% from $64.3 million in the prior year period. Sales for the nine months ended September 30, 2020, were $183.2 million, an increase of 11.1% from $164.9 million in the prior year period. Operating income for the third quarter of 2020 increased by 101.7% from the prior year period due to higher sales.
6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)
6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)
20-F - SINOVAC BIOTECH LTD (0001084201) (Filer)
8-A12B/A - SINOVAC BIOTECH LTD (0001084201) (Filer)
6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)
SC 14D9 - SINOVAC BIOTECH LTD (0001084201) (Subject)
6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)
SC 14D9 - SINOVAC BIOTECH LTD (0001084201) (Subject)
6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)
6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)